Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Up 5.8% in December

Structure Therapeutics Inc. (NASDAQ:GPCR) was the target of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 10,750,000 shares, an increase of 5.8% from the December 15th total of 10,160,000 shares. Based on an average trading volume of 824,600 shares, the short-interest ratio is presently 13.0 days. Currently, 19.8% of the shares of the company are sold short.

Structure Therapeutics Trading Up 0.3 %

NASDAQ GPCR opened at $27.06 on Tuesday. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of -36.57 and a beta of -2.78. Structure Therapeutics has a 12-month low of $23.50 and a 12-month high of $62.74. The business’s 50 day moving average is $30.78 and its two-hundred day moving average is $36.03.

Analyst Ratings Changes

Several research firms recently issued reports on GPCR. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, September 23rd. Stifel Nicolaus assumed coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 target price on the stock. Morgan Stanley began coverage on shares of Structure Therapeutics in a research note on Monday, September 23rd. They set an “overweight” rating and a $118.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a research note on Thursday, December 19th. Finally, JMP Securities restated a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a report on Wednesday, December 18th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $81.29.

Institutional Trading of Structure Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC increased its stake in Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock worth $31,000 after acquiring an additional 1,122 shares during the last quarter. Sandia Investment Management LP acquired a new stake in shares of Structure Therapeutics during the second quarter worth approximately $39,000. FNY Investment Advisers LLC bought a new stake in shares of Structure Therapeutics in the 4th quarter worth about $40,000. Assetmark Inc. raised its stake in Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after buying an additional 719 shares in the last quarter. Finally, Quarry LP bought a new position in Structure Therapeutics during the second quarter worth $79,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.